Reports have it that former French Open finalist Sara Errani has failed a doping test for a hormone that can hide the presence of the male hormone testosterone.
Traces of anastrozole, used in the treatment of breast cancer but also a masking agent, were found in the urine of the 30-year-old former World No 5 during a doping control carried out by the International Tennis Federation, the Gazzetta dello Sport and the Corriere della Sera said.
The tests were carried out in February at her home, the reports said.
Errani was the beaten finalist at Roland Garros in 2012 and reached her highest ever world ranking of five the following year, a meteoric rise for a player who had only just broken into the world top 100.
Errani has previously admitted in 2012 to having treatment from Spanish doctor Luis Garcia Del Moral, who worked with disgraced cyclist Lance Armstrong after the ITF urged players not to receive treatment from him.
“Ms. Errani, a 29-year-old player from Italy, provided a urine sample on 16 February 2017 as part of an Out-of-Competition test under the Programme,” said the ITF in a statement.
“That sample was sent to the WADA-accredited laboratory in Montreal, Canada for analysis, and was found to contain letrozole, which is an aromatase inhibitor that is included under section S4 (Hormone and Metabolic Modulators) of the 2017 WADA Prohibited List, and therefore is also prohibited under the Programme.”
According to the reports Errani, now 98th in the world, was due to play in Canada but has returned to Italy to defend herself ahead of a public announcement expected by the ITF.
The 29-year-old stands to face a 2-month ban starting this August.